MedTrace Logo

Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline

NCT02695446 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-09-14

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate the skin and plasma concentrations of minocycline in subjects undergoing treatment of acne vulgaris with oral extended release minocycline. Acne lesion counts and safety/tolerance of the treatment will also be evaluated.

Conditions

Interventions

DRUG

Minocycline

Oral extended release minocycline

Sponsors & Collaborators

  • BioPharmX, Inc.

    lead INDUSTRY

Principal Investigators

  • Stuart Lessin, MD · KGL, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-04-30
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02695446 on ClinicalTrials.gov